Compare ONEW & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ONEW | MOLN |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.4M | 151.2M |
| IPO Year | 2020 | 2021 |
| Metric | ONEW | MOLN |
|---|---|---|
| Price | $12.91 | $4.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $16.75 | $8.38 |
| AVG Volume (30 Days) | ★ 183.0K | 5.9K |
| Earning Date | 01-29-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,872,334,000.00 | N/A |
| Revenue This Year | $2.23 | N/A |
| Revenue Next Year | $3.55 | $999.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.63 | N/A |
| 52 Week Low | $10.14 | $3.36 |
| 52 Week High | $21.00 | $5.35 |
| Indicator | ONEW | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 50.29 | 49.36 |
| Support Level | $13.18 | $3.97 |
| Resistance Level | $15.25 | $4.27 |
| Average True Range (ATR) | 0.81 | 0.17 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 9.46 | 53.65 |
OneWater Marine Inc is a recreational marine retailer in the United States. The company operates in two segments: Dealership and Distribution. The Dealership segment is involved in selling new and pre-owned boats. It also arranges financing and insurance products, provides repairs and maintenance services, offers marine-related parts and accessories, and supplies slip and storage accommodations at certain locations. The Distribution segment focuses on the manufacturing, assembly, and distribution of marine-related products. These products are supplied to distributors, box retailers, and online retailers through a network of warehouses and distribution centers. The company generates the majority of its revenue from the Dealership segment.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.